PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) approved equity inducement awards for 18 new employees on June 11, 2026, under Nasdaq Listing Rule 5635(c)(4). These include non-statutory stock options for 10,050 shares and 11,870 RSUs, each RSU representing one common share upon vesting.

The stock options have a $74.71 exercise price, a 10-year term, and vest over four years: 25% after one year, then 6.25% quarterly. RSUs vest over four years in 25% annual installments, all subject to continued employment.

AI-generated analysis. Not financial advice.

News Market Reaction – PTCT

+0.34%

29 alerts

+0.34% News Effect

+3.4% Peak in 2 hr 31 min

+$22M Valuation Impact

$6.60B Market Cap

0.7x Rel. Volume

On the day this news was published, PTCT gained 0.34%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $6.60B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 10,050 shares RSUs granted: 11,870 RSUs New employees: 18 employees +5 more

8 metrics

Stock options granted 10,050 shares Non-statutory stock options to new employees under Nasdaq inducement exception

RSUs granted 11,870 RSUs Restricted stock units to 18 new employees as employment inducement

New employees 18 employees Recipients of inducement stock options and RSUs

Option exercise price $74.71 per share Equal to PTCT closing price on June 11, 2026 grant date

Option term 10 years Term of inducement non-statutory stock options

Initial vesting cliff 25% after 1 year Stock options vesting schedule from employee new hire date

Ongoing option vesting 6.25% quarterly Stock options vest each three-month period after first anniversary

RSU vesting 25% annually over 4 years RSUs vest on each annual anniversary of new hire date

Peers on Argus

PTCT is down 4.56% while close biotech peers are mixed (e.g., MRUS -7.08%, KRYS ...

PTCT is down 4.56% while close biotech peers are mixed (e.g., MRUS -7.08%, KRYS +5.6%, CRSP +0.69%), pointing to stock-specific pressure rather than a sector-wide move.

Historical Context

5 past events · Latest: Jun 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jun 15	Convertible notes pricing	Neutral	-4.6%	Pricing of $500M 0% 2031 convertible notes and partial 2026 note refinancing.
Jun 15	Convertible notes proposal	Neutral	+2.2%	Announcement of proposed $500M 2031 convertible note offering and planned buybacks.
May 07	Q1 2026 earnings	Positive	+14.3%	Strong Q1 revenue and raised 2026 guidance alongside clinical updates.
May 04	Investor conferences	Neutral	+0.5%	Participation in multiple healthcare investor conferences with webcast presentations.
Apr 28	PIVOT-HD topline data	Positive	-8.1%	Positive 24-month PIVOT-HD votoplam data showing dose-dependent slowing on cUHDRS.

Pattern Detected

Reactions to news have been mixed: strong rally on Q1 earnings but a sharp selloff on positive PIVOT-HD data and weakness around the recent convertible notes refinancing.

Regulatory & Risk Context

Short Interest: 13.91%

Short Interest

13.91% of shares outstanding

as of 2026-05-29 Days to cover: 11.08

Market Pulse Summary

This announcement details inducement equity grants totaling 10,050 options and 11,870 RSUs at an exe...

Analysis

This announcement details inducement equity grants totaling 10,050 options and 11,870 RSUs at an exercise price of $74.71, a routine hiring-related action. With short interest at 12.72%, future corporate updates could drive outsized volatility.

Key Terms

non-statutory stock options, restricted stock units, nasdaq inducement grant exception, nasdaq listing rule 5635(c)(4)

4 terms

non-statutory stock options financial

"approved non-statutory stock options to purchase an aggregate of 10,050 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq inducement grant exception regulatory

"The awards were made pursuant to the Nasdaq inducement grant exception as a component"

A Nasdaq inducement grant exception is a narrow rule that lets a listed company give stock or options to a newly hired employee without first getting shareholder approval, provided the award meets strict size, timing and disclosure conditions. For investors it matters because such grants can dilute existing shares, signal how the company attracts talent, and affect executive incentives—similar to a signing bonus paid partly in stock instead of cash.

nasdaq listing rule 5635(c)(4) regulatory

"with the company in accordance with Nasdaq Listing Rule 5635(c)(4).All stock option awards"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $74.71 per share, the closing price of PTC's common stock on June 11, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302803422.html

SOURCE PTC Therapeutics, Inc.

FAQ

What inducement equity grants did PTC Therapeutics (NASDAQ: PTCT) approve on June 11, 2026?

PTC Therapeutics approved non-statutory stock options for 10,050 shares and 11,870 RSUs for 18 new employees. According to PTC Therapeutics, each RSU equals one common share upon vesting and the grants serve as employment inducement compensation.

What is the exercise price and term of the new PTC Therapeutics (PTCT) stock options?

The new stock options have a $74.71 exercise price and a 10-year term. According to PTC Therapeutics, $74.71 was the June 11, 2026 closing price of PTCT shares, and options were granted as part of inducement awards.

How do the PTC Therapeutics (PTCT) inducement stock options vest for new employees?

The inducement stock options vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. According to PTC Therapeutics, vesting depends on each employee’s continued service through the applicable vesting dates.

What is the vesting schedule for PTC Therapeutics (PTCT) inducement RSUs granted in June 2026?

The inducement RSUs vest over four years, with 25% of shares vesting on each annual anniversary of the hire date. According to PTC Therapeutics, vesting is contingent on the employee remaining in service through each vesting date.

Why were the June 2026 PTC Therapeutics (PTCT) equity awards made under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as inducement compensation material to each new employee’s acceptance of employment. According to PTC Therapeutics, Nasdaq Listing Rule 5635(c)(4) allows equity grants without shareholder approval when used as hiring inducement.

How many new employees received PTC Therapeutics (PTCT) inducement equity grants in June 2026?

Eighteen new employees received inducement equity awards consisting of stock options and RSUs. According to PTC Therapeutics, these grants were approved by the Compensation Committee on June 11, 2026, as part of their employment compensation packages.